Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

▤ Summary

Quoin Pharmaceuticals has completed the formation of a wholly owned Japanese subsidiary to support the planned commercialization of QRX003. The company wants a direct operating presence in Japan so it can work more closely with regulators, clinicians, and patient groups ahead of a possible launch. QRX003 is still in clinical development, with Phase 2 testing underway and a Phase 3 study expected in the second half of 2026. Quoin is also building out commercial infrastructure across its core markets in the United States, Western Europe, and Japan while maintaining partnerships in other countries.

▦ Linked Companies